Carbocisteine unither pharmaceuticals 750mg/10ml sugar-free oral solution in sachet
מדינה: הממלכה המאוחדת
שפה: אנגלית
מקור: myHealthbox
עלון מידע
(PIL)
26-05-2024
מאפייני מוצר
(SPC)
26-05-2024
מרכיב פעיל:
carbocisteine
זמין מ:
Intrapharm Laboratories Limited
קוד ATC:
R05CB03
INN (שם בינלאומי):
carbocisteine
כמות:
750mg/10m
טופס פרצבטיות:
Oral solution in sachet
מסלול נתינה (של תרופות):
Oral use
יחידות באריזה:
box of 10, 12 or 15 sachets
סוג מרשם:
POM - Prescription Only Medicine
תוצרת:
Unither liquid manufacturing
קבוצה תרפויטית:
mucolytic
סממני תרפויטית:
It is indicated in adults and children over 15 years for recent respiratory disorder with expectoration difficulties (difficulty rejecting by spitting out sputum).
מצב אישור:
Authorised
תאריך אישור:
2015-03-26
מאפייני מוצר
Carbocisteine 750mg/10ml sugarfree oral solution in sachet
Summary of Product Characteristics Updated 07Aug2015 | Intrapharm Laboratories Limited
1. Name of the medicinal product
Carbocisteine unither pharmaceuticals 750mg/10ml sugarfree oral solution in sachet
Carbocisteine 750mg/10ml sugarfree oral solution in sachet
2. Qualitative and quantitative composition
Each 10 ml of oral solution contains 750 mg of carbocisteine
Excipients with known effect:
sodium methyl parahydroxybenzoate (E 219) 15mg per dose
sorbitol liquid (noncrystallising)1.3g per dose
maltitol, liquid 1.3g per dose
sodium 97.5mg per dose
ethanol (trace)
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Oral solution in sachet.
Limpid, viscous, light brown solution.
4. Clinical particulars
4.1 Therapeutic indications
This medicine is indicated in adults and children over 15 years for recent respiratory disorder with expectoration
difficulties (difficulty rejecting by spitting out sputum).
4.2 Posology and method of administration
FOR ADULTS AND CHILDREN OVER 15 YEARS ONLY
Oral route.
One 10 ml sachet contains 750 mg of carbocisteine.
The standard dose is 750 mg, 3 times a day, or 1 sachet, 3 times a day.
This medicine is appropriate for patients following a low sugar or low calorie diet.
Treatment duration:
It should be short and not exceed 5 days.
4.3 Contraindications
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
Active peptic ulceration
4.4 Special warnings and precautions for use
Special warning
Productive coughs that represent a fundamental element in bronchialpulmonary defences should be respected.
The association of bronchial mucous modifiers with anticough medicines and/or substances that dry out secretions
(atropinic) is not ra
קרא את המסמך השלם
